Market Research Logo

Open-Angle Glaucoma - Pipeline Review, H2 2015

Open-Angle Glaucoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H2 2015’, provides an overview of the Open-Angle Glaucoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Open-Angle Glaucoma Overview
Therapeutics Development
Pipeline Products for Open-Angle Glaucoma - Overview
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis
Open-Angle Glaucoma - Therapeutics under Development by Companies
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes
Open-Angle Glaucoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Open-Angle Glaucoma - Products under Development by Companies
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes
Open-Angle Glaucoma - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Asahi Kasei Pharma Corp.
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd.
Inotek Pharmaceuticals Corporation
Ocular Therapeutix, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Sanofi
Santen Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Limited
Sylentis S.A.
vTv Therapeutics LLC
Open-Angle Glaucoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(carteolol hydrochloride + latanoprost) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(dorzolamide hydrochloride + latanoprost) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(latanoprost + trabodenoson) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMA-0076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-8535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bamosiran - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimatoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glaucoma-GT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPP-851 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprostene bunod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-9054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPA-6566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-366234 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize CXCR3 for Glaucoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabodenoson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
travoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Open-Angle Glaucoma - Recent Pipeline Updates
Open-Angle Glaucoma - Dormant Projects
Open-Angle Glaucoma - Discontinued Products
Open-Angle Glaucoma - Product Development Milestones
Featured News & Press Releases
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Open-Angle Glaucoma, H2 2015
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2015
Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2015
Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2015
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2015
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2015
Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2015
Open-Angle Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2015
Open-Angle Glaucoma - Pipeline by Sanofi, H2 2015
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015
Open-Angle Glaucoma - Pipeline by Sun Pharmaceutical Industries Limited, H2 2015
Open-Angle Glaucoma - Pipeline by Sylentis S.A., H2 2015
Open-Angle Glaucoma - Pipeline by vTv Therapeutics LLC, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H2 2015
Open-Angle Glaucoma - Dormant Projects, H2 2015
Open-Angle Glaucoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Open-Angle Glaucoma, H2 2015
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report